Federated Investors Inc. PA bought a new stake in Retrophin Inc (NASDAQ:RTRX) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 89,640 shares of the biopharmaceutical company’s stock, valued at approximately $2,444,000. Federated Investors Inc. PA owned about 0.22% of Retrophin as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. boosted its position in Retrophin by 10.1% during the first quarter. Principal Financial Group Inc. now owns 21,228 shares of the biopharmaceutical company’s stock valued at $475,000 after buying an additional 1,950 shares during the period. State Board of Administration of Florida Retirement System boosted its position in Retrophin by 11.7% during the second quarter. State Board of Administration of Florida Retirement System now owns 26,595 shares of the biopharmaceutical company’s stock valued at $725,000 after buying an additional 2,790 shares during the period. New York State Common Retirement Fund boosted its position in Retrophin by 8.8% during the first quarter. New York State Common Retirement Fund now owns 44,500 shares of the biopharmaceutical company’s stock valued at $995,000 after buying an additional 3,600 shares during the period. Swiss National Bank boosted its position in Retrophin by 6.7% during the first quarter. Swiss National Bank now owns 63,700 shares of the biopharmaceutical company’s stock valued at $1,424,000 after buying an additional 4,000 shares during the period. Finally, Quantbot Technologies LP purchased a new stake in Retrophin during the first quarter valued at about $110,000.

NASDAQ RTRX opened at $29.06 on Monday. Retrophin Inc has a 12-month low of $20.09 and a 12-month high of $33.00. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of -19.37 and a beta of 1.07.

Retrophin (NASDAQ:RTRX) last posted its quarterly earnings results on Thursday, July 26th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.21). The business had revenue of $41.33 million for the quarter, compared to analysts’ expectations of $43.22 million. Retrophin had a negative net margin of 46.90% and a negative return on equity of 23.47%. The business’s quarterly revenue was up 6.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.03 earnings per share. equities research analysts anticipate that Retrophin Inc will post -2.08 EPS for the current year.

Several research firms have issued reports on RTRX. BidaskClub upgraded shares of Retrophin from a “hold” rating to a “buy” rating in a research report on Tuesday, August 28th. Canaccord Genuity began coverage on shares of Retrophin in a research report on Friday, August 17th. They set a “buy” rating for the company. Zacks Investment Research lowered shares of Retrophin from a “hold” rating to a “sell” rating in a research report on Tuesday, July 24th. Finally, ValuEngine lowered shares of Retrophin from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 22nd. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $43.00.

In other news, CEO Steve Aselage sold 12,000 shares of the stock in a transaction dated Friday, August 31st. The shares were sold at an average price of $32.00, for a total transaction of $384,000.00. Following the completion of the sale, the chief executive officer now directly owns 257,883 shares in the company, valued at $8,252,256. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 3.67% of the company’s stock.

Retrophin Company Profile

Retrophin, Inc, a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

Featured Story: Outstanding Shares

Want to see what other hedge funds are holding RTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Retrophin Inc (NASDAQ:RTRX).

Institutional Ownership by Quarter for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.